Oncolytic adenoviruses (Ads) constitute a promising new class of anticancer agent. They are
based on the well-studied adenoviral vector system, which lends itself to concept-driven …

In the evolutionary battle between viruses and their hosts, viruses have armed themselves
with weapons to defeat the host's attacks on infected cells. Various proteins encoded in the …

Glioblastoma (GBM) is the most aggressive primary malignant brain cancer and urgently
requires effective treatments. Chimeric antigen receptor T (CAR-T) cell therapy offers a …

A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a
human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic …

Targeted therapy of cancer using oncolytic viruses has generated much interest over the
past few years in the light of the limited efficacy and side effects of standard cancer …

Oncolytic adenoviruses represent an innovative approach to cancer therapy. These vectors
are typically evaluated in immunodeficient mice with human xenograft tumors. However, in …

Oncolytic virotherapy is an emerging experimental treatment platform for cancer therapy.
Oncolytic viruses are replicative-competent viruses that are engineered to replicate …

An international meeting was held on the development and application of replicating viruses
for cancer therapy this past March in Banff, Alberta. In this review, using the presentations at …

Oncolytic adenoviruses are anticancer agents that replicate within tumors and spread to
uninfected tumor cells, amplifying the anticancer effect of initial transduction. We tested …

We recently described an immunocompetent Syrian hamster model for oncolytic
adenoviruses (Ads) that permits virus replication in tumor cells as well as some normal …